As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype
The Hong Kong Exchange grabbed the biotech world’s attention when it changed the rules on a new listing, letting companies without revenue jump into the market. That happened while the Chinese biotech industry suddenly became one of the hottest investment games in the world. And together those two trends were supposed to light a fire you could clearly see from every continent.
But the flames have died down much faster than anticipated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.